Navigation Links
St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

nfluenza, including human influenza due to strains of avian origin. We wish to congratulate our colleagues at St. Jude on the successful conduct of an elegant study which not only confirms but significantly extends the observations of the previous animal study reported last year by NIH showing positive effects of peramivir in a similar model of H5N1 influenza virus infection."

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on January 4, 2007 awarded BioCryst a $102.6 million, four-year contract to develop peramivir for the treatment of seasonal and life-threatening influenza. Funding from the contract will support manufacturing of clinical lots, process validation, clinical studies and other product approval requirements needed for U.S. licensure. BioCryst retains 100% development and commercialization rights to peramivir worldwide other than in Japan and Korea where BioCryst recently established strategic partnerships with Shionogi & CO. in Japan, and Green Cross in Korea.

About Peramivir

Peramivir is a member of the class of antiviral agents that inhibit influenza viral neuraminidase, an enzyme that is essential for the spread of influenza virus within the host. Peramivir is an inhibitor of influenza A and B neuraminidases and certain strains of influenza viruses that may be resistant to available neuraminidase inhibitors are susceptible to peramivir in laboratory tests. At the 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy in September, 2006, data were presented showing that injectable formulations of peramivir were safely administered to healthy subjects at daily doses up to approximately 600 mg. At the same meeting, animal data were presented showing peramivir promoted survival in animals infected with highly pathogenic strains of the H5N1 virus. Peramivir injection has received Fast Track designation f
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/3/2015)... 2015  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... present at the CL King 13 th Annual ... at 11:00 a.m. ET. The conference will be held ... New York City . Abaxis, Inc. ...
(Date:9/3/2015)... Sept. 3, 2015  VirtualScopics, Inc. (NASDAQ: ... imaging solutions, announced today, they are collaborating with ... new philanthropic, epidemiology study partnering with the Ministry ...  VirtualScopics has teamed up with a cardiac sonographer ... image results will be used to identify children ...
(Date:9/3/2015)... , Sept. 3, 2015 Research and ... of the "Investigation Report on China,s Levothyroxine ... Thyroid hormones (TH) have the greatest ... younger ones. Without thyroid hormones mainly promote the ... organs, even the growth hormone (GH) of pipuitary ...
Breaking Medicine Technology:VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 2VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 3VirtualScopics, Inc. Collaborates with Large Pharmaceutical Company on a Philanthropic, Epidemiology Study in Africa 4Investigation Report on China's Levothyroxine Market, 2010-2019 2
... , CRANBURY, N.J. , Feb. 9 ... announced the completion of first cohort dosing in a placebo-controlled, ... dysfunction.  The primary endpoint in this double-blind safety study is ... between 45 and 65 years old.  The study will also ...
... , SAN MATEO, Calif. , ... the leader in high quality 3D Cone Beam Imaging systems for ... as Director of Marketing. , PreXion President/COO Robert Meier ... management team and I look forward to working with him in ...
Cached Medicine Technology:Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 2Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 3Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men 4PreXion, Inc. Announces Appointment of Director of Marketing 2
(Date:9/3/2015)... ... September 03, 2015 , ... BedJet released a new version of its ... on Kickstarter. Today the BedJet v2 pre-order campaign blazed past the $1 ... successful campaigns ever on crowdfunding giant Kickstarter. , Simple to use and beautifully designed, ...
(Date:9/3/2015)... ... ... Real Time Pain Relief (RTPR), makers of the popular rub-on ... signed an official endorsement deal with the company. Originally from New South Wales, Australia, ... at 15. He is an Australian bull riding champion, following in his uncles’ footsteps ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hope For The Warriors® ... 2016. Scholarships are awarded two times each year to spouses or caregivers of ... nonprofit dedicated to restoring a sense of self, restoring the family unit, and ...
(Date:9/3/2015)... GA (PRWEB) , ... September 03, 2015 , ... ... cover the cost of graduated compression garments. However, graduated compression garments are an ... Wound care and lymphedema specialist, Robyn Bjork, was recently sponsored by SIGVARIS ...
(Date:9/3/2015)... SAN FRANCISCO, CA (PRWEB) , ... September 03, ... ... is transforming the real estate investment landscape by connecting accredited and institutional investors ... mezzanine financing products designed to meet demand from both investors and ...
Breaking Medicine News(10 mins):Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 2Health News:BedJet Hits $1 million in Sales in 28 Days on Kickstarter after Shark Tank Rejection 3Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 2Health News:Real Time Pain Relief Sponsors the Talented PBR Bull Rider from Down Under - David Mason 3Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 2Health News:SIGVARIS Supports the Lymphedema Treatment Act to Help Patients with Lymphedema 3Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3
... Imaging Development, LLC, a mobile imaging management company today announces that ... Chief Executive Officer. , ... LAS VEGAS (Business ... a mobile imaging services provider, hired McNamara as Director of Marketing ...
... phase of childbirth can reduce health risks to themselves and ... extra two hours, according to a new study by researchers ... doing so, obstetricians could eliminate more than 130,000 cesarean deliveries ... year in the United States, the researchers conclude. , ...
... Year; Data Demonstrate High, Durable Response Rates for Patients ... ... Pa., Oct. 31 Cephalon, Inc., (Nasdaq:,CEPH) today announced ... TREANDA(R) (bendamustine hydrochloride) for Injection for the,treatment of patients ...
... Can Help Delay or Prevent Diabetes, HARRISBURG, Pa., ... Secretary of Health Everette James today,reminded Pennsylvanians that there ... becoming diabetic., "Diabetes rates continue to rise, making ... in Pennsylvania," said James. "Studies show,many cases of diabetes ...
... heroes to be featured in the December issue of ... the fight against breast cancer, WOODBURY, Minn., Oct. ... and Reader,s Digest have partnered together for the,first time ... real life,Warriors who fight the disease. Reader,s Digest asked ...
... resource center dedicated to providing information and support for patients, ... impact of spinal cord injury, traumatic brain injury, and amputation. ... ... October 31, 2008 -- Catstrophicinjury.com is a new ...
Cached Medicine News:Health News: Mobile Imaging Innovator, Mobile Diagnostic Centers LP, Appoints New CEO : Mobile Imaging Development's Limited Partnership, Mobile Diagnostic Centers LP. Has Appointed Patrick McNamara as CEO 2Health News:Patience during stalled labor can avoid many C-sections, UCSF study shows 2Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4Health News:Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Health News:Health Secretary Raises Awareness About Diabetes; Rising Costs of Treatment 2Health News:Winners Selected as Beautiful Warriors by Ford Warriors in Pink and Reader's Digest for Exemplifying the Fight Against Breast Cancer 2Health News:Winners Selected as Beautiful Warriors by Ford Warriors in Pink and Reader's Digest for Exemplifying the Fight Against Breast Cancer 3Health News:Winners Selected as Beautiful Warriors by Ford Warriors in Pink and Reader's Digest for Exemplifying the Fight Against Breast Cancer 4Health News:New Online Support Site Offers Hope, Information, and Help for Patients Who Have Suffered a Catastrophic Injury 2
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
... up of doublet objective and high power ... and 3.0x. The true benefit of this ... maintaining focal clarity is made possible due ... ultra lightweight aluminum bar and individual interpupillary ...
Used for maintaining and forming the anterior chamber by the injection and removal of fluids, air miotics, and viscoeastic substances, as well as keeping the cornea moist during surgery. 4 mm from be...
23 gauge cannula (E4969 L) with 0.33 mm aspiration port, curved shaft and polished finish. Includes Teflon irrigating sleeve (E4969 SL). Uses 60 cm (23.6 inches) of silicone tubing (N5941 5). Overall...
Medicine Products: